Verastem 8th Annual Wolfe Research Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Welcome, everyone, to our next fireside chat here. I have the Verastem team, Ting Wu and Jonathan Pachter. Thank you both. Thank you to both of you for joining us today. To kick it off, maybe Jonathan or Ting, we have seen a lot of updates in this space lately. You guys had your own comprehensive update for the G12D. Ultimately, the number one question I get is, maybe there is too many fish in one pond here. Where do you guys see yourselves differentiating in the RAS landscape? What do you think investors are still missing about your molecule following the comprehensive update that you just had?
Yeah, I think the differentiation, we feel that for a patient with a KRAS G12D-driven cancer in 2026 or 2027, they deserve an agent that is selective for that variant, and we think that ours is best in class among both G12D and pan-RAS for fulfilling that role. There are several properties of our drug that really stand out. One is being dual on/off really potently, and I think others claim to be that, but I think a problem with some pan-KRAS, for example, is they tend to be off-selective and therefore do not have activity. So I think the dual on/off, we have a long residence time or slow off rate so that, for example, if you see the grade 1, grade 2 GI adverse events, you can stop dosing, but you are still covering target because of that long residence time, which is valuable.
Ours is extremely G12D selective, and KRAS G12D does not mediate any normal function in the body, so that really gives you great tolerability. We do not see rash or stomatitis for that reason. But I think the thing that is probably underappreciated is really simple, is in the RAS space, I think most agents fail to maximally hit the target, and I think that that is for one of two reasons. For some agents, for pharmacological reasons, you dose up and you hit a ceiling, and you cannot keep getting higher exposure. I think zoldonrasib might be an example of that when you look at their PK. Then for the pan-RAS inhibitors, it is more toxicity limited that you just cannot dose to fully hitting the target, and that has led some to combine a couple of different RAS inhibitors of various flavors to try to deal with that.
I think that we can really maximally hit the target, and when you look, for example, at knocking down KRAS G12D variant allele frequency, we clearly do that much better than others, and it is reflected in the clinical data as well that we shared that Ting will talk about more. So I think there are many properties that are really best in class about our agent. What is misunderstood or not picked up? I think a couple points. One is I think the world is moving toward that appreciation that even though pan-RAS or pan-KRAS, if there was ever one good enough, could be a larger market, I think that the world is really moving toward variant selective. I think if there is a variant driving your cancer, you want to be something really selective for that. I see that shift in the last six months. People are appreciating that. People are thinking, "What's the best G12D selective?" as opposed to, "How would you ever compete with the pan-RAS space?" The second thing that I think is maybe misunderstood or not thought about as well as it should be is the value of single-agent activity.
I think that many of the RAS inhibitors, if they have insufficient efficacy on their own, they might obfuscate that by combining very quickly and showing you what the combination does with EGFR or with chemotherapy, and I think it's really about your drug. I think that for durable response, for example, in pancreatic cancer, you can't only rely on the combinations.
I think that, for example, when you treat with chemotherapy, you might, for the first two or three cycles, you might give full dose chemotherapy, but then you're dropping out day eight of day one, eight, 15, you're dropping the doses, and then by four or six cycles, you're not giving chemotherapy anymore because it's not tolerated. So, it's your drug underlying that you really have to depend on, and we're very combinable, so we are doing those combinations, but I think that as you're comparing between drugs, it's really important to understand what the single agent does as a starting point.
Got it. Okay. One of the more common questions we've received for you guys is the 600 milligram dose versus the 900 milligram dose, the choice of going towards the 900, whereas your partner GenFleet has not done that, or I don't think is planning to do that. Is there any evidence, I guess we have some empirical evidence so far, but anything that suggests that the 900 is going to be materially better than the 600?
Yeah. Thanks for the question, Kalpit, and I think we can look at it in three ways. The first one is, of course, the clinical data, and the disclosure of the data we have disclosed is that there's a clear dose relationship between the 600 and 900 milligram. The dose response is pretty clear. I think that's the most, I would say, direct evidence. The second thing is about the PK, because the 600 and 900 PK is dose proportional. It's a meaningful increase from 600 to 900 milligram, give you more confidence that there's a different exposure that leads to the dose response. The third point is about the safety and tolerability, is that the tolerability profile for 900 and 600 milligrams are identical.
Mostly the doses are limited by safety or tolerability, but we don't see a difference. If you see a dose response, you should pick the higher dose. Those are, I would say, evidence at this point that give us confidence that 900 is a go for a dose. Regarding GenFleet, I think it's more about they haven't fully characterized 900 mg. As you probably noticed, they only dosed three patients at 900 mg and did not fully explore that dose and decided to go for a speed for 600 mg. This is not the first time where in different countries there are different approval doses. Just an example, lenvatinib has a lower dose in Japan, as an example. I don't think that's kind of unique, but it's more like, okay, did you fully explore the dose?
If there's any kind of racial differences there that we need to continue to explore further.
It's also intriguing when you look at the waterfall plots with our RAS inhibitor and different RAS inhibitors. If, again, to my point of wanting to maximally hit the target, if you are submaximal, you look at the left side of the waterfall, you see tumor growth is the best response for some patients. I think at 600, we see that sometimes. At 900, across indications, we never see that. Our waterfall's only full. That's also showing the value of 900 versus 600 as being the right dose.
What would be a good outcome for you guys for PFS and maybe ORR and PFS difference between the 600 and 900 doses?
Yeah. Firstly, I believe that we have sufficient data to support 900 milligram as a go-forward dose. I frame it as less of a comparison, but what 900 milligram would need to achieve. I think the clearest benchmark, probably in PDAC, because there are RAS inhibitors out there for standard of care in G12D. I would say something that we demonstrated, like 40% north of a single-agent activity in a previously treated, and a PFS probably north of seven to nine months is what we are aiming for. I think one of the things is that we continue to observe is that our datasets, that as data mature, I think we are moving towards that kind of goal that we want to achieve. For the 22-patient dataset at PDAC 900 milligram that we disclosed, we will have a follow-up on PFS in future medical conferences.
Regarding 900 milligrams, it is important to emphasize that 900 will be our go-forward across indications, across cancer indications. We are probably getting to the point where we are hoping across combinations as well. We have DLT cleared 900 with anti-EGFR. We have DLT cleared it with gem nab paclitaxel. As to the combinations with chemo or chemo-IO for frontline colorectal and lung, we are in the process of clearing those. Ultimately, our expectation at this point is that 900 would be well tolerated with those as well.
Okay. When looking at safety, one of the other common questions we have gotten is the China dataset safety seemed a little better than the Western dataset safety, if you look at the publication from GenFleet.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
